[Current approach to the treatment of pulmonary arterial hypertension and our experience in the Cardiology Department of Medicine Faculty of Ege University].
Pulmonary arterial hypertension is a progressive disease marked by increased pulmonary artery resistance leading to right heart failure and has very high mortality. Survival rates have somewhat improved in recent years due to the development of new drugs and early diagnosis. This review aims to summarize the current therapeutic approach to pulmonary arterial hypertension and share our experience at our center.
Kayikçioğlu
Meral
M
Ege Universitesi Tip Fakültesi Kardiyoloji Anabilim, Dali, Izmir, Turkey. meral.kayikcioglu@ege.edu.tr
Kültürsay
Hakan
H
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004110:Diltiazem / Q000627:therapeutic use; D018450:Disease Progression; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D016285:Iloprost / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D014421:Turkey; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol; D004110:Diltiazem; D009543:Nifedipine; D016285:Iloprost